Dupilumab in chronic rhinosinusitis with nasal polyposis: current status, challenges, and future perspectives

References

• Cho SH, Hamilos DL, Han DH, et al. Phenotypes of chronic rhinosinusitis. J Allergy Clin Immunol Pract. 2020;8(5):1505–1511. doi: 10.1016/j.jaip.2019.12.021
   PubMed Web of Science ®Google Scholar
• Marin C, Hummel T, Liu Z, et al. Chronic rhinosinusitis and COVID-19. J Allergy Clin Immunol Pract. 2022;10(6):1423–1432. doi: 10.1016/j.jaip.2022.03.003
   PubMed Web of Science ®Google Scholar
• Laidlaw TM, Mullol J, Woessner KM, et al. Chronic rhinosinusitis with nasal polyps and asthma. J Allergy Clin Immunol Pract. 2021;9(3):1133–1141. doi: 10.1016/j.jaip.2020.09.063
   PubMed Web of Science ®Google Scholar
• Bachert C, Bhattacharyya N, Desrosiers M, et al. Burden of disease in chronic rhinosinusitis with nasal polyps. J Asthma Allergy. 2021;14:127–134. doi: 10.2147/JAA.S290424
   PubMed Web of Science ®Google Scholar
• Hirsch AG, Stewart WF, Sundaresan AS, et al. Nasal and sinus symptoms and chronic rhinosinusitis in a population-based sample. Allergy. 2017;72(2):274–281. doi: 10.1111/all.13042
   PubMed Web of Science ®Google Scholar
• Smith KA, Smith TL, Mace JC, et al. Endoscopic sinus surgery compared to continued medical therapy for patients with refractory chronic rhinosinusitis. Int Forum Allergy Rhinol. 2014;4(10):823–827. doi: 10.1002/alr.21366
   PubMed Web of Science ®Google Scholar
• van der Lans RJL, Hopkins C, Senior BA, et al. Biologicals and endoscopic sinus surgery for severe uncontrolled chronic rhinosinusitis with nasal polyps: an economic perspective. J Allergy Clin Immunol Pract. 2022;10(6):1454–1461.
   PubMed Web of Science ®Google Scholar
• Mullol J, Azar A, Buchheit KM, et al. Chronic rhinosinusitis with nasal polyps: quality of life in the biologics era. J Allergy Clin Immunol Pract. 2022;10(6):1434–1453.e9. doi: 10.1016/j.jaip.2022.03.002
   PubMed Web of Science ®Google Scholar
• Fokkens WJ, Lund V, Bachert C, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019;74(12):2312–2319. doi: 10.1111/all.13875
   PubMed Web of Science ®Google Scholar
• Zhang Y, Gevaert E, Lou H, et al. Chronic rhinosinusitis in Asia. J Allergy Clin Immunol. 2017;140(5):1230–1239. doi: 10.1016/j.jaci.2017.09.009
   PubMed Web of Science ®Google Scholar
• Bachert C, Gevaert P, Hellings P. Biotherapeutics in chronic rhinosinusitis with and without nasal polyps. J Allergy Clin Immunol Pract. 2017;5(6):1512–1516. doi: 10.1016/j.jaip.2017.04.024
   PubMed Web of Science ®Google Scholar
• Brescia G, Alessandrini L, Zanotti C, et al. Histopathological and hematological changes in recurrent nasal polyposis. Int Forum Allergy Rhinol. 2019;9(7):813–820. doi: 10.1002/alr.22314
   PubMed Web of Science ®Google Scholar
• Kamal MA, Franchetti Y, Lai CH, et al. Pharmacokinetics and concentration-response of dupilumab in patients with seasonal allergic rhinitis. J Clin Pharmacol. 2022;62(5):689–695. doi: 10.1002/jcph.2004
   PubMed Web of Science ®Google Scholar
• Li Z, Radin A, Li M, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of dupilumab in healthy adult subjects. Clin Pharmacol Drug Dev. 2020;9(6):742–755. doi: 10.1002/cpdd.798
   PubMed Web of Science ®Google Scholar
• Kato A. Immunopathology of chronic rhinosinusitis. Allergol Int. 2015;64(2):121–130. doi: 10.1016/j.alit.2014.12.006
   PubMed Web of Science ®Google Scholar
• Naclerio RM, Baroody FM. Other phenotypes and treatment of chronic rhinosinusitis. J Allergy Clin Immunol Pract. 2016;4(4):613–620. doi: 10.1016/j.jaip.2016.03.016
   PubMed Web of Science ®Google Scholar
• Schneider S, Campion NJ, Villazala-Merino S, et al. Associations between the quality of life and nasal polyp size in patients suffering from chronic rhinosinusitis without nasal polyps, with nasal polyps or aspirin-exacerbated respiratory disease. J Clin Med. 2020 [Published 2020 Mar 28];9(4):925. doi: 10.3390/jcm9040925.
   PubMed Web of Science ®Google Scholar
• Bachert C, Marple B, Schlosser RJ, et al. Adult chronic rhinosinusitis. Nat Rev Dis Primers. 2020 [Published 2020 Oct 29];6(1):86. doi: 10.1038/s41572-020-00218-1.
   PubMed Web of Science ®Google Scholar
• Abdalla S, Alreefy H, Hopkins C. Prevalence of sinonasal outcome test (SNOT-22) symptoms in patients undergoing surgery for chronic rhinosinusitis in the England and Wales National prospective audit. Clinical Otolaryngology: Official Journal Of ENT-UK; Official Journal Of Netherlands Society For Oto-Rhino-Laryngology & Cervico-Facial Surgery. 2012;37(4):276–282. doi: 10.1111/j.1749-4486.2012.02527.x
   PubMed Web of Science ®Google Scholar
• Feng T, Miao P, Liu B, et al. Sinus microbiota in patients with eosinophilic and non-eosinophilic chronic rhinosinusitis with nasal polyps. Front Cell Infect Microbiol. 2021 [Published 2021 Jul 23];11:672355.
   PubMed Web of Science ®Google Scholar
• De Corso E, Bilò MB, Matucci A, et al. Personalized management of patients with chronic rhinosinusitis with nasal polyps in clinical practice: a multidisciplinary consensus statement. J Pers Med. 2022 [Published 2022 May 23];12(5):846. doi: 10.3390/jpm12050846.
   PubMed Web of Science ®Google Scholar
• Ryu G, Kim DW. Th2 inflammatory responses in the development of nasal polyps and chronic rhinosinusitis. Curr Opin Allergy Clin Immunol. 2020;20(1):1–8. doi: 10.1097/ACI.0000000000000588
   PubMed Web of Science ®Google Scholar
• Khan A, Huynh TMT, Vandeplas G, et al. The GALEN rhinosinusitis cohort: chronic rhinosinusitis with nasal polyps affects health-related quality of life. Rhinology. 2019;57(5):343–351. doi: 10.4193/Rhin19.158
   PubMed Web of Science ®Google Scholar
• Bao K, Reinhardt RL. The differential expression of IL-4 and IL-13 and its impact on type-2 immunity. Cytokine. 2015;75(1):25–37. doi: 10.1016/j.cyto.2015.05.008
   PubMed Web of Science ®Google Scholar
• Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425–437. doi: 10.1080/1744666X.2017.1298443
   PubMed Web of Science ®Google Scholar
• Stevens WW, Peters AT, Tan BK, et al. Associations between inflammatory endotypes and clinical presentations in chronic rhinosinusitis. J Allergy Clin Immunol Pract. 2019;7(8):2812–2820.e3. doi: 10.1016/j.jaip.2019.05.009
   PubMed Web of Science ®Google Scholar
• Mortuaire G, Gengler I, Carpentier C, et al. T helper 2 inflammatory markers are associated with recurrence in chronic rhinosinusitis with nasal polyps after endoscopic sinus surgery. Rhinology. 2020;58(5):444–450. doi: 10.4193/Rhin19.439
   PubMed Web of Science ®Google Scholar
• Floc’h A L, Allinne J, Nagashima K, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020;75(5):1188–1204. doi: 10.1111/all.14151
   PubMed Web of Science ®Google Scholar
• Hamilton JD, Harel S, Swanson BN, et al. Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases. Clin Exp Allergy. 2021;51(7):915–931. doi: 10.1111/cea.13954
   PubMed Web of Science ®Google Scholar
• Yu J, Xian M, Piao Y, et al. Changes in clinical and histological characteristics of nasal polyps in Northern China over the past 2-3 decades. Int Arch Allergy Immunol. 2021;182(7):615–624. doi: 10.1159/000513312
   PubMed Web of Science ®Google Scholar
• Van Crombruggen K, Zhang N, Gevaert P, et al. Pathogenesis of chronic rhinosinusitis: inflammation. J Allergy Clin Immunol. 2011;128(4):728–732. doi: 10.1016/j.jaci.2011.07.049
   PubMed Web of Science ®Google Scholar
• Wang C, Yan B, Zhang L. The epithelium-derived inflammatory mediators of chronic rhinosinusitis with nasal polyps. Expert Rev Clin Immunol. 2020;16(3):293–310. doi: 10.1080/1744666X.2020.1723417
   PubMed Web of Science ®Google Scholar
• Canonica GW, Bourdin A, Peters AT, et al. Dupilumab demonstrates rapid onset of response across three type 2 inflammatory diseases. J Allergy Clin Immunol Pract. 2022;10(6):1515–1526. doi: 10.1016/j.jaip.2022.02.026
   PubMed Web of Science ®Google Scholar
• Pelaia C, Heffler E, Crimi C, et al. Interleukins 4 and 13 in asthma: key pathophysiologic cytokines and druggable molecular targets. Front Pharmacol. 2022 [Published 2022 Mar 8];13:851940.
   PubMed Web of Science ®Google Scholar
• Kariyawasam HH. Chronic rhinosinusitis with nasal polyps: mechanistic insights from targeting IL-4 and IL-13 via IL-4Rα inhibition with dupilumab. Expert Rev Clin Immunol. 2020;16(12):1115–1125. doi: 10.1080/1744666X.2021.1847083
   PubMed Web of Science ®Google Scholar
• Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA. 2016;315(5):469–479. doi: 10.1001/jama.2015.19330
   PubMed Web of Science ®Google Scholar
• Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials [published correction appears in Lancet. 2019 Nov 2;394(10209): 1618]. Lancet. 2019;394(10209):1638–1650. doi: 10.1016/S0140-6736(19)31881-1
   PubMed Web of Science ®Google Scholar
• Jonstam K, Swanson BN, Mannent LP, et al. Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis. Allergy. 2019;74(4):743–752. doi: 10.1111/all.13685
   PubMed Web of Science ®Google Scholar
• Schneider JS. Subcutaneous dupilumab and mometasone furoate nasal spray for chronic rhinosinusitis with polyps. JAMA Otolaryngology–Head & Neck Surg. 2016;142(7):698–699. doi: 10.1001/jamaoto.2016.0678
   PubMed Web of Science ®Google Scholar
• Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475–2485. doi: 10.1056/NEJMoa1804093
   PubMed Web of Science ®Google Scholar
• Salvati L, Liotta F, Annunziato F, et al. Therapeutical targets in allergic inflammation. Biomedicines. 2022 [Published 2022 Nov 9];10(11):2874. doi: 10.3390/biomedicines10112874.
   PubMed Web of Science ®Google Scholar
• Bachert C, Hellings PW, Mullol J, et al. Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma. J Allergy Clin Immunol Pract. 2019;7(7):2447–2449.e2. doi: 10.1016/j.jaip.2019.03.023
   PubMed Web of Science ®Google Scholar
• Bachert C, Zinreich SJ, Hellings PW, et al. Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP. Rhinology. 2020;58(1):10–17. doi: 10.4193/Rhin18.282
   PubMed Web of Science ®Google Scholar
• Bachert C, Hellings PW, Mullol J, et al. Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis. Allergy. 2020;75(1):148–157. doi: 10.1111/all.13984
   PubMed Web of Science ®Google Scholar
• Hellings PW, Akdis CA, Bachert C, et al. EUFOREA rhinology research forum 2016: report of the brainstorming sessions on needs and priorities in rhinitis and rhinosinusitis. Rhinology. 2017;55(3):202–210. doi: 10.4193/Rhin17.028
   PubMed Web of Science ®Google Scholar
• De Corso E, Settimi S, Montuori C, et al. Effectiveness of dupilumab in the treatment of patients with severe uncontrolled CRSwNP: a “real-life” observational study in the first year of treatment. J Clin Med. 2022 [Published 2022 May 10];11(10):2684. doi: 10.3390/jcm11102684.
   PubMed Web of Science ®Google Scholar
• De Corso E, Pasquini E, Trimarchi M, et al. Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): a multicentric observational Phase IV real-life study (DUPIREAL) [published online ahead of print, 2023 May 18]. Allergy. 2023; doi: 10.1111/all.15772
   Web of Science ®Google Scholar
• Grose E, Li AY, Lee JM. Clinical outcomes of dupilumab therapy in chronic rhinosinusitis with nasal polyps in a Canadian tertiary care rhinology practice. Allergy, Asthma Clin Immunol. 2023 [Published 2023 Mar 30];19(1):26. doi: 10.1186/s13223-023-00782-7.
   PubMed Web of Science ®Google Scholar
• Kariyawasam HH, James LK, Gane SB. Dupilumab: clinical efficacy of blocking IL-4/IL-13 signalling in chronic rhinosinusitis with nasal polyps. Drug Des Devel Ther. 2020 [Published 2020 May 8];14:1757–1769. doi: 10.2147/DDDT.S243053
   PubMed Web of Science ®Google Scholar
• Luong AU, Chua A, Alim BM, et al. Allergic fungal rhinosinusitis: the role and expectations of biologics. J Allergy Clin Immunol Pract. 2022;10(12):3156–3162. doi: 10.1016/j.jaip.2022.08.021
   PubMed Web of Science ®Google Scholar
• Loftus CA, Soler ZM, Koochakzadeh S, et al. Revision surgery rates in chronic rhinosinusitis with nasal polyps: meta-analysis of risk factors. Int Forum Allergy Rhinol. 2020;10(2):199–207. doi: 10.1002/alr.22487
   PubMed Web of Science ®Google Scholar
• Alotaibi NH, Aljasser LA, Arnaout RK, et al. A case report of allergic fungal rhinosinusitis managed with Dupilumab. Int J Surg Case Rep. 2021;88:106479. doi: 10.1016/j.ijscr.2021.106479
   PubMed Web of Science ®Google Scholar
• Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials [published correction appears in J Allergy Clin Immunol. 2021 Jan;147(1): 416]. J Allergy Clin Immunol. 2020;146(3):595–605. doi: 10.1016/j.jaci.2020.05.032
   PubMed Web of Science ®Google Scholar
• Weinstein SF, Katial RK, Bardin P, et al. Effects of reslizumab on asthma outcomes in a subgroup of eosinophilic asthma patients with self-reported chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract. 2019;7(2):589–596.e3. doi: 10.1016/j.jaip.2018.08.021
   PubMed Web of Science ®Google Scholar
• Tversky J, Lane AP, Azar A. Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): a randomized double-blind placebo-controlled trial. Clin Exp Allergy. 2021;51(6):836–844. doi: 10.1111/cea.13852
   PubMed Web of Science ®Google Scholar
• Detoraki A, Tremante E, D’Amato M, et al. Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study. Ther Adv Respir Dis. 2021;15:17534666211009398. doi: 10.1177/17534666211009398
   Web of Science ®Google Scholar
• Fokkens W, Van Der Lans R, Reitsma S. Dupilumab for the treatment of chronic rhinosinusitis with nasal polyposis. Expert Opin Biol Ther. 2021;21(5):575–585. doi: 10.1080/14712598.2021.1901881
   PubMed Web of Science ®Google Scholar
• Kariyawasam HH, James LK. Chronic rhinosinusitis with nasal polyps: targeting IgE with Anti-IgE Omalizumab Therapy. Drug Des Devel Ther. 2020;14: 5483–5494. Published 2020 Dec 10. 10.2147/DDDT.S226575.
   PubMed Web of Science ®Google Scholar
• El-Qutob D. Off-label uses of omalizumab. Clin Rev Allergy Immunol. 2016;50(1):84–96. doi: 10.1007/s12016-015-8490-y
   PubMed Web of Science ®Google Scholar
• Lipworth B, Chan R, Kuo CR. Omalizumab or dupilumab for chronic rhinosinusitis with nasal polyposis. J Allergy Clin Immunol. 2021;147(1):413. doi: 10.1016/j.jaci.2020.09.024
   PubMedGoogle Scholar
• Gevaert P, Lang-Loidolt D, Lackner A, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol. 2006;118(5):1133–1141. doi: 10.1016/j.jaci.2006.05.031
   PubMed Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115–2127. doi: 10.1016/S0140-6736(16)31324-1
   PubMed Web of Science ®Google Scholar
• Keating GM. Mepolizumab: first global approval. Drugs. 2015;75(18):2163–2169. doi: 10.1007/s40265-015-0513-8
   PubMed Web of Science ®Google Scholar
• Pitlick MM, Li JT, Pongdee T. Current and emerging biologic therapies targeting eosinophilic disorders. World Allergy Organ J. 2022 [Published 2022 Jul 31];15(8):100676. doi: 10.1016/j.waojou.2022.100676.
   PubMed Web of Science ®Google Scholar
• Markham A. Reslizumab: first global approval [published correction appears in Drugs. 2016 Jul;76(11): 1159]. Drugs. 2016;76(8):907–911. doi: 10.1007/s40265-016-0583-2
   PubMed Web of Science ®Google Scholar
• Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020;75(5):1023–1042. doi: 10.1111/all.14221
   PubMed Web of Science ®Google Scholar
• Farne HA, Wilson A, Milan S, et al. Anti-IL-5 therapies for asthma. Cochrane Database Syst Rev. 2022;7(7): CD010834. Published 2022 Jul 12. doi:10.1002/14651858.CD010834.pub4.
   PubMedGoogle Scholar
• Korn S, Bourdin A, Chupp G, et al. Integrated safety and efficacy among patients receiving benralizumab for up to 5 years. J Allergy Clin Immunol Pract. 2021;9(12):4381–4392.e4. doi: 10.1016/j.jaip.2021.07.058
   PubMed Web of Science ®Google Scholar
• Bachert C, Han JK, Desrosiers MY, et al. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2022;149(4):1309–1317.e12. doi: 10.1016/j.jaci.2021.08.030
   PubMed Web of Science ®Google Scholar
• De Prado G, Khan L, Peters AT, et al. Efficacy and safety of dupilumab versus omalizumab in chronic rhinosinusitis with nasal polyps and asthma: eVEREST Trial Design. Am J Rhinol Allergy. 2022;36(6):788–795. doi: 10.1177/19458924221112211
   PubMed Web of Science ®Google Scholar
• Peters AT, Han JK, Hellings P, et al. Indirect treatment comparison of biologics in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract. 2021;9(6):2461–2471.e5. doi: 10.1016/j.jaip.2021.01.031
   PubMed Web of Science ®Google Scholar
• Gevaert P, Van Bruaene N, Cattaert T, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol. 2011;128(5):989–95.e958. doi: 10.1016/j.jaci.2011.07.056
   PubMed Web of Science ®Google Scholar
• Fokkens WJ, Mullol J, Kennedy D, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): in-depth sinus surgery analysis. Allergy. 2023;78(3):812–821. doi: 10.1111/all.15434
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–2141. doi: 10.1016/S0140-6736(16)31322-8
   PubMed Web of Science ®Google Scholar
• Bleecker ER, Wechsler ME, FitzGerald JM, et al. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. Eur Respir J. 2018 [Published 2018 Oct 18];52(4):1800936. doi: 10.1183/13993003.00936-2018.
   PubMed Web of Science ®Google Scholar
• Hellings PW, Verhoeven E, Fokkens WJ. State-of-the-art overview on biological treatment for CRSwNP. Rhinology. 2021;59(2):151–163. doi: 10.4193/Rhin20.570
   PubMed Web of Science ®Google Scholar
• Cai S, Xu S, Lou H, et al. Comparison of different biologics for treating chronic rhinosinusitis with nasal polyps: a network analysis. J Allergy Clin Immunol Pract. 2022;10(7):1876–1886.e7. doi: 10.1016/j.jaip.2022.02.034
   PubMed Web of Science ®Google Scholar
• Oykhman P, Paramo FA, Bousquet J, et al. Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta-analysis. J Allergy Clin Immunol. 2022;149(4):1286–1295. doi: 10.1016/j.jaci.2021.09.009
   PubMedGoogle Scholar
• Orlandi RR, Kingdom TT, Hwang PH, et al. International consensus statement on allergy and rhinology: rhinosinusitis. Int Forum Allergy Rhinol. 2016;6(Suppl 1):S22–S209. doi: 10.1002/alr.21694
   PubMed Web of Science ®Google Scholar
• Calus L, Van Bruaene N, Bosteels C, et al. Twelve-year follow-up study after endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyposis. Clin Transl Allergy. 2019 [Published 2019 Jun 14];9(1):30. doi: 10.1186/s13601-019-0269-4.
   PubMedGoogle Scholar
• DeConde AS, Mace JC, Levy JM, et al. Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis. Laryngoscope. 2017;127(3):550–555. doi: 10.1002/lary.26391
   PubMed Web of Science ®Google Scholar
• Bachert C, Zhang N, Hellings PW, et al. Endotype-driven care pathways in patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2018;141(5):1543–1551. doi: 10.1016/j.jaci.2018.03.004
   PubMed Web of Science ®Google Scholar
• Dessouky O, Hopkins C. Surgical versus medical interventions in CRS and nasal polyps: comparative evidence between medical and surgical efficacy. Curr Allergy Asthma Rep. 2015;15(11):66. doi: 10.1007/s11882-015-0566-5
   PubMed Web of Science ®Google Scholar
• Workman AD, Welling DB, Carter BS, et al. Endonasal instrumentation and aerosolization risk in the era of COVID-19: simulation, literature review, and proposed mitigation strategies. Int Forum Allergy Rhinol. 2020;10(7):798–805. doi: 10.1002/alr.22577
   PubMed Web of Science ®Google Scholar
• Fujieda S, Matsune S, Takeno S, et al. Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS-52 is unaffected by eosinophilic status. Allergy. 2022;77(1):186–196. doi: 10.1111/all.14906
   PubMed Web of Science ®Google Scholar
• Deleuran M, Thaçi D, Beck LA, et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol. 2020;82(2):377–388. doi: 10.1016/j.jaad.2019.07.074
   PubMed Web of Science ®Google Scholar
• Hopkins C, Wagenmann M, Bachert C, et al. Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol. 2021;11(7):1087–1101. doi: 10.1002/alr.22780
   PubMed Web of Science ®Google Scholar
• Aldajani A, Alroqi A, Alromaih S, et al. Adverse events of biological therapy in chronic rhinosinusitis with nasal polyps: a systematic review. Am J Otolaryngol. 2022;43(6):103615. doi: 10.1016/j.amjoto.2022.103615
   PubMed Web of Science ®Google Scholar
• Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130–139. doi: 10.1056/NEJMoa1314768
   PubMed Web of Science ®Google Scholar
• Reich K, Thyssen JP, Blauvelt A, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. Lancet. 2022;400(10348):273–282. doi: 10.1016/S0140-6736(22)01199-0
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Ford LB, Maspero JF, et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med. 2022;10(1):11–25. doi: 10.1016/S2213-2600(21)00322-2
   PubMed Web of Science ®Google Scholar
• de Loos DA D, Hopkins C, Fokkens WJ. Symptoms in chronic rhinosinusitis with and without nasal polyps. Laryngoscope. 2013;123(1):57–63. doi: 10.1002/lary.23671
   PubMed Web of Science ®Google Scholar
• van der Lans RJL, van Spronsen E, Fokkens WJ, et al. Complete remission of severe eosinophilic otitis media with dupilumab: a case report. Laryngoscope. 2021;131(12):2649–2651. doi: 10.1002/lary.29730
   PubMed Web of Science ®Google Scholar
• Parasher AK, Gliksman M, Segarra D, et al. Economic evaluation of dupilumab versus endoscopic sinus surgery for the treatment of chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol. 2022;12(6):813–820. doi: 10.1002/alr.22936
   PubMed Web of Science ®Google Scholar
• Brown WC, Senior B. A critical look at the efficacy and costs of biologic therapy for chronic rhinosinusitis with nasal polyposis. Curr Allergy Asthma Rep. 2020 [Published 2020 Apr 22];20(6):16. doi: 10.1007/s11882-020-00910-y.
   PubMed Web of Science ®Google Scholar
• van der Lans RJL, Fokkens WJ, Adriaensen GFJPM, et al. Real-life observational cohort verifies high efficacy of dupilumab for chronic rhinosinusitis with nasal polyps. Allergy. 2022;77(2):670–674. doi: 10.1111/all.15134
   PubMed Web of Science ®Google Scholar
• Agache I, Song Y, Alonso-Coello P, et al. Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: a systematic review for the EAACI guidelines. Allergy. 2021;76(8):2337–2353. doi: 10.1111/all.14809
   PubMed Web of Science ®Google Scholar